For generations, the management of cholesterol has been a daily act of discipline — a pill taken each morning as a quiet acknowledgment of the body's fragility. Now, two clinical trials, one spanning the United States, Australia, New Zealand, and Britain, and another in China, suggest that a single injection using CRISPR gene-editing technology may one day replace that ritual entirely, silencing a liver gene called ANGPTL3 to mimic a natural mutation that protects certain people from heart disease. The science draws its logic not from invention but from observation — nature has already shown t